65 results
10-Q
2021 Q1
EX-10.2
KIN
Kindred Biosciences Inc
Quarterly report
11 May 21
4:11pm
10-K
2020 FY
EX-10.29
KIN
Kindred Biosciences Inc
Annual report
16 Mar 21
4:06pm
10-K
2020 FY
EX-10.26
KIN
Kindred Biosciences Inc
Annual report
16 Mar 21
4:06pm
10-K
2020 FY
EX-10.12
KIN
Kindred Biosciences Inc
Annual report
16 Mar 21
4:06pm
10-K
2020 FY
EX-10.30
KIN
Kindred Biosciences Inc
Annual report
16 Mar 21
4:06pm
8-K
EX-10.1
gztp6
5 Aug 20
Kindred Biosciences Announces Second Quarter 2020 Financial Results
4:09pm
8-K
EX-10.1
jd3j1 tb41k
17 Jun 20
Departure of Directors or Certain Officers
4:04pm
8-K
EX-10.1
hdzvi6uj31y mrw58dv2
8 Apr 20
Entry into a Material Definitive Agreement
4:04pm
8-K
EX-10.1
d5131915x5r0 m8
16 Mar 20
Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial Results
4:08pm
8-K
EX-10.1
mlytxb8m o98
2 Oct 19
Kindred Biosciences Secures $50 Million Debt Facility with Solar Capital Partners
4:18pm
8-K
EX-10.1
h3ixz4
29 May 18
Departure of Directors or Certain Officers
4:04pm
8-K
EX-10.3
rvuomoon
29 May 18
Departure of Directors or Certain Officers
4:04pm
8-K
EX-10.4
xz7 utunqwo875i
29 May 18
Departure of Directors or Certain Officers
4:04pm
8-K
EX-10.2
l6odyxqxluk6p8ap
29 May 18
Departure of Directors or Certain Officers
4:04pm
8-K
EX-10.1
9kkf3
7 May 18
Kindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats
7:05am